Sir,

I read with interest the report entitled "A case of *Aerococcus urinae* vertebral osteomyelitis" by Jerome *et al*.\[[@ref1]\] published in Journal of Global Infectious Diseases, Volume 7, issue 2. The authors describe a 37-year-old male with back pain, who was diagnosed with spondylodiscitis. The bone specimen cultures grew, according to the authors, *A. urinae*. Case reports that describe rare but serious conditions caused by aerococci are important and add valuable information to the field.

Jerome *et al*. claim that their case is the first reported. Vertebral osteomyelitis, more commonly denoted spondylitis, caused by aerococci is a rare condition, but it has been described at least three times previously.\[[@ref2][@ref3][@ref4]\] Aerococci have been hard to classify, and misidentification has occurred frequently.\[[@ref4][@ref5]\] It is, therefor, important to use reliable identification methods to identify aerococci such as matrix-assisted laser desorption ionization - time of flight mass spectrometry or sequencing of 16S rRNA gene. The species identification method described in the case report by Jerome *et al*. is not sufficient to separate aerococcal species from each other. It is, therefor, not possible to securely claim *A. urinae* as the causative agent to this case of spondylodiscitis. Moreover, spondylodiscitis is potentially a complication to infective endocarditis, and it would be valuable to know if blood cultures were collected and if any additional work-up was performed.

If *A. urinae* is part of the normal human flora is not known. Jerome *et al*. claim that *A. urinae* is a commensal in the urinary tract, but there is no reference to support this statement. It would be of great interest to know where the authors have found this information. The patient in the case report received cefazolin, a first-generation cephalosporin, for 6 weeks. The authors do not comment on why the patient was switched from the initial empiric treatment with vancomycin and piperacillin-tazobactam to cefazolin when amoxicillin would be a more rational treatment option.
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